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Poster Session I 53syndrome (HPS) early after cord blood transplantation (CBT). Al-
though both can be serious and potentially fatal, not much data have
been available regarding their mechanisms underlying them. Re-
cently, we observed a group of patients who presented relative lym-
phocytosis (LC) early after CBTbefore engraftment.We decided to
conduct a retrospective analysis of those who presented LC early af-
ter transplant to characterize clinical features and to evaluate possi-
ble relevance to abovementioned immune-mediated complications.
Patients and Definition: Patients who underwent RI-CBT at
our institute from Jan.2005 to July 2007 were retrospectively re-
viewed. LC was defined by early lymphocyte-dominant ($80%) in-
crease of WBC for at least 3 consecutive days. Lymphocyte count
must be over 200/ul at least once. Result: We observed 11 cases
who presented LC. Eight out of 11 were of donor-type and 3 of re-
cipient-type chimerism. Median onset of LC of donor cells was 8.5
(8–10) days, and the maximum number of lymphocyte was 519
(242–2828)/ul, primarily CD3-positive T cells with CD4–81 dom-
inancy (60.6(13–68.1)%). Fever and diarrhea were observed in all
patients, liver damage in 7, skin eruption in 4, and HPS in 6. Six
out of 8 experienced graft failure, whereas the remaining 2 experi-
enced severe acute GVHD, resulted in 6 early death up to 50 days
post-transplant. LC of recipient cells developed on median 13
(12–16) days post-transplant, and themaximumnumber of lympho-
cyte was 550 (280–880)/ul, in which CD4–81 cells dominated
(93.1(83.1–96.6)%). All 3 experienced graft rejection and 2 of
them were rescued by second RI-CBT, while 1 died of infection.
Conclusion: LC of either donor- or recipient-derived was sugges-
tive of high incidence of graft failure. Further analyses are currently
going on to investigate possible relevance of LC to PIR or HPS.
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NOR FROM A SEARCH THROUGH THE NMDP? A 10 YEAR, SINGLE INSTI-
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Askar, M.1, Sobecks, R.2, Kalaycio, M.2, Dean, R.2, Copelan, E.2,
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TheNationalMarrowDonor Program (NMDP) continues to ex-
pand its donor pool. Transplant outcome correlates with the degree
of HLA matching. Ideally, NMDP searches result in fully matched
donors at the allele level. The odds of finding such a donor, how-
ever, has not been widely discussed.
We performed a retrospective analysis of 517 searches to the
NMDP fromNovember, 1996 through November, 2006. Of these,
213 resulted in a transplant. This analysis is limited to the patients
that actually proceeded to transplant because of multiple potential
reasons beyond HLA matching that may have prevented patients
from receiving a transplant. Only 36 (17%) of 213 transplanted pa-
tients had donors that were fully matched at the allele level. Ninety-
four (44%) patients were mismatched at only DP. Sixty-seven
(31%) patients had a class 1, or DRB1mismatch. The median dura-
tion from the initiation from NMDP search to transplant was 5.2
months. We conclude that finding fully matched donors is still
a challenge, and highlights the need for continued recruitment
for volunteers to the NMDP registry. Indeed, a result of 17% is
likely an overestimate of the number of fully matched searches, be-
cause this analysis only included the patients who proceeded to
transplant. Additionally, 8/8 matched donors with DP mismatches
are common.
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There is a need for better control of graft versus host disease
(GVHD) after HLA mismatched peripheral blood stem cell
(PBSC) allogeneic transplantation. Bortezomib is a small moleculeproteasome inhibitor approved for treatment of multiple myeloma.
It has immunomodulatory properties, and preclinical data indicate
utility in GVHD control after allogeneic transplantation. Here we
report the dose finding portion of a Phase I/II trial of bortezomib
(dose levels A, B, C: 1, 1.3, 1.5 mg/m2) plus tacrolimus and mini-
methotrexate for GVHD prophylaxis after HLA mismatched non
myeloablative allogeneic stem cell transplantation (NST) for pa-
tients with hematologic malignancies. Dose limiting toxicity
(DLT) by day 45 post PBSC infusion is the primary endpoint,
both acute bortezomib toxicity (e.g. neuropathy) and negative im-
pact on stem cell function (e.g. delayed neutrophil recovery or
poor donor engraftment) in the absence of disease progression. Sec-
ondary endpoints include incidence of acute and chronic GVHD.
Patients with 1–2 locus antigen/allele mismatch (HLA-A, -B, -C,
-DRB1) were eligible. Pretransplant conditioning was busulfex (0.8
mg/kg/d) and fludarabine (30 mg/m2/d) each for 4 days. GVHD
prophylaxis was bortezomib per dose level (day 11, 14, 17) plus
tacrolimus (day –3 to 1180) and mini-methotrexate (5 mg/m2 on
day 11, 13, 16, 111).
13 patients were enrolled. No neurotoxicity was noted. At dose
level A, 1 of 5 patients had a possible DLT, with poor engraftment
likely related to progression of underlying MDS/AML. At dose
level B, 0 of 3 patients had a DLT. At dose level C, 2 of 5 patients
had a DLT. One patient, with minimally treated myeloproliferative
disease failed to engraft; another patient, with CLL, experienced an
immunologic graft rejection.
Grade 2–4 aGVHD occurred in 2 of 13 patients (1 each at dose
level A and C). Chronic GVHD occurred in 3 patients, all at dose
level A, albeit with limited follow up. Disease relapse has occurred
in 5 patients (2 of whomdied), one at dose level B, and 2 each at dose
levels A and C. In summary, GVHD prophylaxis with bortezomib
1.3 mg/m2 plus tacrolimus/mini-methotrexate is convenient and
well tolerated after busulfex/fludarabine conditioning in HLA mis-
matched NST. It may have efficacy in GVHD control, and phase II
accrual is proceeding.LATE EFFECTS/QUALITY OF LIFE141
SIMILAR RISKS FOR HYPOTHYROIDISM IN MYELOABLATIVE AND RE-
DUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
SURVIVORS
Al-Hazzouri, A., Cao, Q., Burns, L.J., Weisdorf, D.J., Majhail, N.S.
University of Minnesota, Minneapolis, MN.
Upto 15% of adult myeloablative (MA) allogeneic hematopoietic
cell transplant (HCT) survivors can develop hypothyroidism. HCT
using reduced-intensity conditioning (RIC) is associated with lower
morbidity and mortality, but the risk of hypothyroidism after RIC
HCT is not known. We conducted a retrospective cohort study
to compare the incidence of hypothyroidism after MA and RIC
HCT. Adult allogeneic HCT recipients were eligible if (1) they
had received an allogeneic HCT using a total body irradiation
(TBI) based MA or RIC regimen between 2000 and 2005, (2) sur-
vived for$1 year post-HCT, and (3) had no history of hypothyroid-
ism pre-HCT. TBI dose in MA and RIC regimens was 1320 cGy
(165 cGy twice daily 4 days) and 200 cGy (single fraction), respec-
tively. Hypothyroidism was classified as subclinical (elevated thy-
roid stimulating hormone [TSH] and normal free thyroxine
[FT4]) or overt (elevated TSH and low FT4). All patients had thy-
roid studies performed at least annually after HCT; if clinically in-
dicated, more frequent assessments were conducted at the
discretion of the treating physician. Study eligibility criteria were
met by 181 patients (MA 5 84, RIC 5 97); median follow-up was
28 (range, 12–75) months for MA and 25 (range, 12–67) months
for RIC group. MA recipients were younger (median age 37 vs.
54 years, P \ 0.01), the two groups were otherwise comparable
with respect to gender, race, HCT co-morbidity index scores, dis-
ease status, donor source and incidences of acute and chronic
GVHD. Eleven patients developed hypothyroidism (subclinical -
9, overt - 2). The 3-year cumulative incidence of hypothyroidism
was 8% (95% confidence intervals [CI], 1–14%) in MA and 5%
(95%CI, 0–11%) in RIC groups (p5 0.41). Inmultivariate analyses
that included age, gender, race, conditioning regimen intensity,
